ICYMI: LA TIMES – VACCINE MAKER GOT $1 BILLION FROM TAXPAYERS. NOW IT’S BOOSTING DRUG PRICES

09-15-2020 Blog Posts

Brand Name Drug Maker AstraZeneca Aggressively Raised Prices In The Middle Of A Pandemic, Even While Receiving Hundreds Of Millions In Taxpayer Funding Vaccine Maker Got $1 Billion From Taxpayers. Now It’s Boosting Drug Prices Los Angeles Times Noam N. Levey September 14, 2020 https://www.latimes.com/politics/story/2020-09-14/drug-maker-got-1-billion-from-taxpayers-boosting-prices One of the world’s largest drug companies has been aggressively […]

ICYMI: STUDY SHOWS BIG PHARMA’S ANTI-COMPETITIVE GAMESMANSHIP COMES AT TREMENDOUS COST TO U.S. HEALTHCARE SYSTEM

09-14-2020 Blog Posts

Report Finds Just Five Instances Of Product Hopping Sticks Americans With $4.7 Billion Price Tag In case you missed it, a new study by Alex Brill of Matrix Global Advisors (MGA), commissioned by the Coalition for Affordable Prescription Drugs (CAPD), demonstrates the tremendous cost to the U.S. healthcare system from just one of the many […]

ICYMI: REPORT CONFIRMS REBATE RULE WOULD HIKE PREMIUMS, COST TAXPAYERS BILLIONS OF DOLLARS AND BOOST “DRUG COMPANY REVENUES”

09-8-2020 Blog Posts

Study Finds Rebates Negotiated By PBMs Reduce Rx Costs and Lower Premiums – Eliminating Rebates Would Increase Costs On American Seniors & Taxpayers, While Handing Big Pharma a Bailout In case you missed it, a new report by Alex Brill of Matrix Global Advisors (MGA) confirms the administration’s misguided reboot of the Rebate Rule would […]

ICYMI: STAT NEWS – NEW POLL SHOWS WIDE SUPPORT FOR SEVERAL TRUMP DRUG PRICING REFORMS, BUT NOT REBATE CHANGES

08-28-2020 Blog Posts

Administration Should Shelve Rebate Rule That Would Increase Medicare Premiums, Cost Taxpayers $200 Billion and Hand Big Pharma a Massive Bailout In case you missed it, a new poll first reported by STAT News on Friday highlights how the “Rebate Rule is the Achilles Heel of the president’s drug pricing agenda.” The survey found the […]

DOSE OF REALITY: TRUMP ADMINISTRATION MUST DUMP REBATE RULE TO ACHIEVE SECOND TERM GOAL OF LOWERING PREMIUMS

08-26-2020 Blog Posts

Misguided Measure Would Increase Medicare Part D Premiums, Cost Taxpayers More Than $200 Billion and Do Nothing To Lower Prescription Drug Prices On Monday, the Trump Administration released a list of second term health care priorities, which included “lowering healthcare insurance premiums.” If the administration is going to be successful in accomplishing that goal, it […]

DOSE OF REALITY: DEBUNKING BIG PHARMA’S SUPPLY CHAIN BLAME GAME

08-14-2020 Blog Posts

Drug Companies Target PBMs and Rebates That Play a Critical Role in Lowering Drug Prices to Evade Responsibility and Boost Their Bottom Line Big Pharma has long tried to evade culpability for the crisis of rising prescription drug prices by pointing a finger at others in the drug supply chain. Drug companies, in particular, have […]

BIG PHARMA EARNINGS WATCH: BRISTOL-MYERS SQUIBB

08-6-2020 Blog Posts

Brand Name Drug Company Completes Sweep of Big Pharma Giants Who Beat Wall Street Expectations After 2020 Price Hikes In a final round of second quarter earnings reports, another Big Pharma giant announced they surpassed earnings expectations after hiking prices on American patients. Bristol-Myers Squibb reported sky-high profits after hiking prices on American patients earlier […]

DOSE OF REALITY: UNPACKING THE REBATE RULE’S BIG PHARMA ORIGINS

08-3-2020 Blog Posts

Little Surprise Big Pharma Bailout That Would Hike Medicare Premiums Was A Drug Company Idea The Origins of a Big Pharma Bailout Would you be surprised to learn a controversial idea to hand Big Pharma a more than $100 billion bailout while increasing Medicare premiums and costing taxpayers billions originated with a Big Pharma company? […]

BIG PHARMA EARNINGS WATCH: ABBVIE & MERCK

07-31-2020 Blog Posts

Brand Name Drug Companies Continue Streak of Beating Wall Street Expectations After Price Hikes Two more Big Pharma giants announced Friday they surpassed earnings expectations after hiking prices on American patients. AbbVie and Merck both reported sky-high profits after hiking prices on American patients earlier this year. AbbVie Sales increased to $10.4 billion compared to […]

Big Pharma Earnings Watch: AstraZeneca & Eli Lilly

07-31-2020 Blog Posts

Brand Name Drug Companies See Soaring Profits After Hiking Prices Today, brand name drug giants AstraZeneca and Eli Lilly announced rising profits for the second quarter of 2020 – topping analysts’ expectations. AstraZeneca AstraZeneca reported a net profit of $756 million, up from $130 million for the same period a year earlier. Sales rose eight […]

Sign-up for updates

  • This field is for validation purposes and should be left unchanged.